ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "skin"

  • Abstract Number: 0545 • ACR Convergence 2021

    SIRT1 Modulates the Senescent Phenotype in Scleroderma Endothelial Cells

    Ellen Model, Morgan Omara, Pamela Palisoc, Dinesh Khanna and Eliza Pei-Suen Tsou, University of Michigan, Ann Arbor, MI

    Background/Purpose: Vascular abnormalities in systemic sclerosis (SSc) are characterized by injury to vascular wall and extensive damage of the microvessels. It has been shown that…
  • Abstract Number: 0546 • ACR Convergence 2021

    Integrated Analysis of Dermal Blister Fluid Proteomics and Genome-wide Skin Gene Expression Gives New Insight into Pathogenesis of Systemic Sclerosis

    Kristina Clark1, Eszter Csomor2, Corrado Campochiaro3, Adam Taylor4, Yee Voan Teo2, Katherine Nevin2, Mary Morse2, Voon Ong5, Emma Derrett-Smith6, Nicolas Wisniacki2, Shaun Flint2 and Christopher Denton7, 1University College London, London, United Kingdom, 2GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, 3Royal Free Hospital London, London, United Kingdom, 4GlaxoSmithKline, London, United Kingdom, 5University College London Medical School Royal Free Campus, London, United Kingdom, 6University College London Division of Medicine, London, United Kingdom, 7University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom

    Background/Purpose: Suction blister fluid provides a unique opportunity to analyse the dermal microenvironment of SSc. We report an integrated analysis of proteomic data from dermal…
  • Abstract Number: 0555 • ACR Convergence 2021

    Pathway-Driven Drug Repositioning in Systemic Sclerosis from Omics Data

    Dillon Popovich1, Tamar Abel1, Noelle Kosarek2, Monica Espinoza3, Rezvan Parvizi4, Jonathan Garlick5 and Michael Whitfield4, 1Geisel School of Medicine, West Lebanon, NH, 2Dartmouth Geisel School of Medicine, Hartford, VT, 3Geisel School of Medicine, Hanover, NH, 4Geisel School of Medicine, Lebanon, NH, 5Tufts University School of Dental Medicine, Boston, MA

    Background/Purpose: Omic analyses of systemic sclerosis (SSc) skin biopsy datasets identified distinct sets of patients that respond differently to treatment. The goal of this study…
  • Abstract Number: 0557 • ACR Convergence 2021

    The Beta Secretase BACE1 Induces Systemic Sclerosis (SSc) Fibroblast Activation Through the Regulation of the Pro-Fibrotic Notch Signalling Pathway

    Christopher Wasson1, Eva Clavane2, Rebecca Ross1, Paul Meakin2 and Francesco Del Galdo3, 1LIRMM University of Leeds, Leeds, United Kingdom, 2LICAMM University of Leeds, Leeds, United Kingdom, 3University of Leeds, Leeds, United Kingdom

    Background/Purpose: Extensive work in the Alzheimer’s field has shown BACE1 plays an important role in amyloid beta processing. Additionally, there is evidence showing BACE1 regulating…
  • Abstract Number: 0966 • ACR Convergence 2021

    Integrated Single Cell RNA-Sequencing Analysis of Tissue-Localized T Cells in Cutaneous Lupus and Lupus Nephritis

    Garett Dunlap1, Allison Billi2, Feiyang Ma3, Johann Gudjonsson2, J. Michelle Kahlenberg4 and Deepak Rao5, 1Harvard University, Somerville, MA, 2Department of Dermatology, University of Michigan, Ann Arbor, MI, 3University of California Los Angeles, Los Angelas, CA, 4University of Michigan, Ann Arbor, MI, 5Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Cutaneous lupus erythematosus (CLE) is commonly present in patients with systemic lupus erythematosus (SLE), but can also exist as an isolated manifestation without further…
  • Abstract Number: 1437 • ACR Convergence 2021

    Fat and Fibrosis: A Novel Developmental Gene in Systemic Sclerosis

    Nancy Wareing1, Brian Skaug2, Minghua Wu3, Scott Collum1, Cory Wilson1, Lucy Revercomb4, Marka Lyons5, Weizhen Bi6, Tingting Mills1, Julio Charles5, Shervin Assassi1 and Harry Karmouty-Quintana1, 1University of Texas McGovern Medical School at Houston, Houston, TX, 2University of Texas McGovern Medical School Houston, Houston, TX, 3University of Texas Health Science Center at Houston, Houston, TX, 4Rice University, Houston, TX, 5Division of Rheumatology, University of Texas McGovern Medical School at Houston, Houston, TX, 6McGovern Medical School at UTHealth, Houston, TX

    Background/Purpose: Early loss of skin-associated adipose tissue and concomitant replacement by extracellular matrix is a hallmark of systemic sclerosis (SSc). However, the contribution of adipose…
  • Abstract Number: 1491 • ACR Convergence 2021

    Single-cell Analysis of Paired Skin and Blood Samples from Patients with SLE and Cutaneous Lupus Suggests CD16+ DCs Arise from Non-classical Monocytes That Enter Nonlesional Skin, Undergo Type I IFN Education, and Engage in Extensive Crosstalk with Diverse Immune and Stromal Cell Types

    Allison Billi1, Feiyang Ma2, Olesya Plazyo3, Grace Hile3, Xianying Xing3, Mehrnaz Gharaee-Kermani4, Rachael Wasikowski3, Lam Tsoi3, Matteo Pellegrini2, Robert L. Modlin2, Johann Gudjonsson1 and J. Michelle Kahlenberg3, 1Department of Dermatology, University of Michigan, Ann Arbor, MI, 2University of California Los Angeles, Los Angeles, CA, 3University of Michigan, Ann Arbor, MI, 4Internal Medicine - Division of Rheumatology and Department of Dermatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Cutaneous lupus erythematosus (CLE) is an incompletely understood autoimmune disease that can occur in isolation or in the context of SLE. CLE is often…
  • Abstract Number: 1495 • ACR Convergence 2021

    Multiplexed Profiling of Treatment Naïve Cutaneous Lupus Skin Stratified by Patient Response to Antimalarials

    Thomas Vazquez1, Jay Patel2, Daisy Yan3, Emily Keyes4, DeAnna Diaz5, Yubin Li6, Madison Grinnell6, Rui Feng7 and Victoria Werth3, 1FIU Wertheim College of Medicine, Virginia Beach, VA, 2Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, NJ, 3Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 4Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, 5Philadelphia College of Medicine, Philadelphia, PA, 6Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, PA, 7University of Pennsylvania Department of Biostatistics, Philadelphia, PA

    Background/Purpose: Lupus erythematous (LE) is a systemic autoimmune disease with a variety of cutaneous manifestations. Antimalarials are first-line systemic therapy, yet not all patients respond…
  • Abstract Number: 1759 • ACR Convergence 2021

    An Analysis of Medication Responsiveness Based on Subtype and Race Within a Cohort of Cutaneous Lupus Erythematosus Patients

    Emily Keyes1, Anisha Jobanputra2, Madison Grinnell3, Rui Feng4, Thomas Vazquez5, DeAnna Diaz6 and Victoria Werth7, 1Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, 2Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, OMAHA, NE, 4University of Pennsylvania Department of Biostatistics, Philadelphia, PA, 5FIU Wertheim College of Medicine, Virginia Beach, VA, 6Philadelphia College of Medicine, Philadelphia, PA, 7Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Cutaneous lupus erythematosus (CLE) can present in association with or without concomitant SLE, and with skin manifestations varying by subtype – acute CLE, subacute…
  • Abstract Number: 1784 • ACR Convergence 2021

    Characterizing Musculoskeletal Disease Burden in Mild to Moderate Psoriasis Patients Suggestive of Comorbid PsA: Analysis of CorEvitas’ Psoriasis Registry

    Alexis Ogdie-Beatty1, Bruce Strober2, Mark Lebwohl3, Angel Cronin4, Tin-chi Lin4, Hyung-Joo Kang4, Nicole Middaugh4, Jacqueline O’Brien4, Shauna Jardon5, Sven Richter6, Yuri Klyachkin7 and Philip Mease8, 1University of Pennsylvania, Philadelphia, PA, 2Yale University, New Haven, CT, 3Icahn School of Medicine at Mount Sinai, New York, NY, 4CorEvitas, LLC, Waltham, MA, 5Amgen Inc., Gilbert, AZ, 6Amgen Inc., Thousand Oaks, CA, 7Amgen Inc., Lexington, KY, 8Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA

    Background/Purpose: Patients (pts) with mild to moderate psoriasis (PsO) and musculoskeletal disease burden may be diagnosed with PsA upon referral to a rheumatologist. Early intervention…
  • Abstract Number: 1857 • ACR Convergence 2021

    Ultra-High Frequency Ultrasound Compared to Durometry and Skin Score for Cutaneous Assessment in Systemic Sclerosis

    Marco Di Battista1, Saverio Vitali2, Simone Barsotti3, Alessandra Della Rossa4, Valentina Dini5, Marco Romanelli5 and Marta Mosca3, 1Rheumatology Unit, University of Pisa, Pisa, Italy, 2Radiology Unit - University of Pisa, Pisa, Italy, 3Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 4Rheumatology Unit - University of Pisa, Pisa, Italy, 5Dermatology Unit - University of Pisa, Pisa, Italy

    Background/Purpose: To assess skin involvement in a cohort of patients with systemic sclerosis (SSc) comparing results obtained from modified Rodnan skin score (mRSS), durometry and…
  • Abstract Number: L09 • ACR Convergence 2020

    A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)

    Dinesh Khanna1, Christopher Denton2, Daniel Furst3, Maureen Mayes4, Marco Matucci-Cerinic5, Vanessa Smith6, Dick de Vries7, Liesbeth Deberdt8, Pieter‑Jan Stiers8, Niyati Prasad8 and Sohail Ahmed9, 1University of Michigan, Ann Arbor, MI, 2Royal Free Hospital, University College London, London, United Kingdom, 3David Geffen School of Medicine at UCLA, Los Angeles, CA, 4University of Texas Health Science Center at Houston, Houston, TX, 5Università degli Studi di Firenze, Firenze, Italy, 6Ghent University Hospital, Ghent, Belgium, 7Galapagos BV, Leiden, Netherlands, 8Galapagos NV, Mechelen, Belgium, 9Ahmed Science Medicine, Basel, Switzerland

    Background/Purpose: There is a high unmet need for systemic sclerosis (SSc) treatments. Ziritaxestat (ziri; GLPG1690) is an autotaxin inhibitor with a novel mechanism of action.…
  • Abstract Number: L10 • ACR Convergence 2020

    Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734

    Victoria Werth1, Jodi Karnell2, William Rees2, Nanette Mittereder3, Li Yan2, Yanping Wu3, Jorn Drappa2, Gabor Illei2 and John Ratchford2, 1University of Pennsylvania, Philadelphia, PA, 2Viela Bio, Gaithersburg, MD, 3Viela Bio, Gaithersburg

    Background/Purpose: Plasmacytoid dendritic cells (pDCs) secrete large amounts of type I interferon (IFN) and other cytokines upon activation. pDCs migrate to sites of active disease…
  • Abstract Number: 0402 • ACR Convergence 2020

    Optical Coherence Tomography of the Skin Detects Scleroderma Changes in Clinically Unaffected Skin: An Opportunity for Early Detection of Systemic Sclerosis

    Giuseppina Abignano1, Duygu Temiz Karadag2, Ozcan Gundogdu3, Giovanni Lettieri4, Maria Carmela Padula5, Angela A Padula5, Paul Emery6, Salvatore D'Angelo5 and Francesco Del Galdo6, 1Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Potenza, Italy, 2Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy and Department of Rheumatology, Kocaeli University, Kocaeli, Turkey, Kocaeli, Turkey, 3Department of Biomedical Engineering, Kocaeli University, Kocaeli,Turkey, Kocaeli, Turkey, 4Radiology Department, San Carlo Hospital, Potenza, Italy, Potenza, Italy, 5Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, Potenza, Italy, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom

    Background/Purpose: The Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) study has shown that more than 80% of patients with Raynaud’s Phenomenon, specific ANA positivity and…
  • Abstract Number: 0512 • ACR Convergence 2020

    Efficacy of Apremilast for the Treatment of Manifestations of Behçet’s Syndrome Other Than Oral Ulcers, Including Skin Lesions and Arthritis

    Gülen Hatemi1, Alfred Mahr2, Mitsuhiro Takeno3, Doyoung Kim4, Melike Melikoğlu1, Sue Cheng5, Sven Richter5, Michele Brunori6, Maria Paris5, Mindy Chen5 and Yusuf Yazici7, 1Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, Istanbul, Turkey, 2Cantonal Hospital St. Gallen, St. Gallen, Switzerland, 3Nippon Medical School, Graduate School of Medicine, Tokyo, Japan, 4Yonsei University College of Medicine and Severance Hospital, Seoul, Republic of Korea, 5Amgen Inc., Thousand Oaks, 6Amgen Europe GmbH, Rotkreuz, Switzerland, 7New York University School of Medicine, New York

    Background/Purpose: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by painful and recurrent oral ulcers (OU) and other manifestations, such as skin lesions and…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology